Recruiting

Genetic Counseling Models

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT05420064

Conditions

BRCA1 Mutation

POLD1 Gene Mutation

CDKN2A Mutation

BRCA2 Mutation

POLE Gene Mutation

Eligibility Criteria

Sex: All

Age: 25+

Healthy Volunteers: Accepted

Interventions

Intervention Arm At-risk Relative/ARR Contacts

MyGene Portal

Standard of Care

Study Details

Brief summary:

The purpose of this study is to examine the impact of new cancer genetic counseling models that aim to increase patient engagement with the genetics team. To do this, the study consists of two trials to evaluate two related interventions. The first trial is the EfFORT Trial, which evaluates a cascade genetic testing intervention. Cascade testing is the process of offering genetic testing to people who are at risk of having inherited a possibly harmful gene change that has been found in their family. The study will look at how often genetic testing occurs when healthcare providers have permission to reach out to family members to recommend genetic testing and to help those who are interested get tested. The study will look at whether this cascade testing intervention is practical and effective. The study would like to see how this approach of healthcare providers reaching out directly to family members compares with the usual approach of patients telling their family members about the recommendation to get genetic testing. The second trial is the STRIVE Trial, which evaluates an intervention designed to help patients who receive an uncertain result from genetic testing (also called a "variant of uncertain significance") stay connected with their genetics care team, and to help patients and their primary care providers stay up-to-date about the meaning of uncertain genetic test results. The study will look at whether an intervention that consists of a study online portal for patients with uncertain genetic test results and their primary care providers will help them to stay up-to-date on the meaning of uncertain genetic test results. The study would like to see how this intervention compares to the usual approach of encouraging patients to re-contact their genetics care team on their own about a year after getting genetic testing."

Conditions

BRCA1 Mutation

POLD1 Gene Mutation

CDKN2A Mutation

BRCA2 Mutation

POLE Gene Mutation

Study ID

NCT05420064

Start date

Dec 1, 2022

Status verified date

Aug, 2026

Completion date

Nov 30, 2027

Anticipated

Primary completion date

May 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 25+

Healthy Volunteers: Accepted

Inclusion Criteria:

EfFORT Trial Probands

  • Current MSK patient
  • Received post-test genetic counseling from MSK Clinical Genetics Service within the last 3 months (or within the last year for the de-identified non-randomized control probands)
  • 25 years of age or older
  • Self-reported "very well" comprehension of written and verbal English language or Spanish language
  • Has at least one ARR who meets criteria for study enrollment (see below)
  • First in the family to test positive for PV at MSK in any of the following cancer susceptibility genes, or an ARR of an MSK proband who converted to the proband role:

APC I1307K, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDKN2A (P16), CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, BAP1, DICER1, FH, FLCN, HOXB13, KIT, MAX, MEN1, MET, MITF, PTCH1, RAD51B, RET, SDHB, SDHC, SDHD, STK11, SUFU, TMEM127, TSC1, TSC2, VHL

Principal Investigator discretion will be used to determine whether specific variants within the above genes meet a clinical actionability threshold to warrant familial genetic testing.

EfFORT Trial At-Risk Relatives (ARRs):

  • Biological first-, second-, or third- degree relative of enrolled MSK proband
  • 25 years of age or older
  • Resides within the United States
  • Self-reported medical insurance which can be in or out of network with MSK
  • Self-reported "very well" comprehension of written and verbal English language

STRIVE Trial VUS Patients

  • Current MSK patient
  • Received post-test genetic counseling from MSK Clinical Genetics Service within the last 3 months
  • 25 years of age or older
  • Self-reported "very well" comprehension of written and verbal English language or Spanish language
  • Has a VUS identified in any of the following cancer predisposition genes:

APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (P16), CHEK2, CTNNA1, DICER1, ELOC, EPCAM, FH, FLCN, GREM1, HOXB13, KEAP1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RET, RNF43, RPS20, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, STK11, TERT, TMEM127, TP53, TSC1, TSC2, VHL

STRIVE Trial PCP Providers:

  • Designated healthcare provider for an enrolled VUS patient
  • Resides within the United States

Exclusion Criteria:

EfFORT Trial Probands

  • Is unwilling or unable to provide informed consent
  • Is unwilling or unable to create a MyMSK patient portal account (see section 3.0 on MyMSK patient usage at MSK and CGS)
  • Does not have an email address
  • Has enrolled in the STRIVE trial

EfFORT Trial At-Risk Relatives (ARRs):

  • Is unwilling or unable to provide informed consent
  • Is unwilling or unable to create a MyMSK patient portal account
  • Has previously undergone genetic testing for the familial PV
  • Does not have an email address
  • Has opted out of study contact

STRIVE Trial VUS Patients

  • Is unwilling or unable to provide informed consent
  • Is unwilling or unable to create a MyMSK patient portal account (see section 3.0 on MyMSK patient usage at MSK and CGS)
  • Does not have an email address
  • Has enrolled in the EfFORT trial

STRIVE Trial PCP Providers

  • Contact information not available

Study Design

Enrollment

1000 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

active comparator: Proband-Mediated Cascade Genetic Testing

Control arm- Behavioral: As per standard of care, probands will be given a Family Letter by their genetic counselor that they will be instructed to share with their at-risk relatives (ARR). In addition to the recommendation that ARR undergo genetic counseling and a list of local genetics clinics, this letter will include a link to the eDGP through which control ARR can enroll onto the present study. For these ARR, the eDGP will only be used to obtain study e-consent and to administer study surveys.

experimental: EfFORT Trial Intervention Arm: Provider-Facilitated Cascade Genetic Testing

Intervention arm-: Behavioral: Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.

active comparator: STRIVE Trial Control Arm: Patient-Led VUS Follow-Up

Patients will receive standard of care post-test genetic counseling and discussion of implications for relatives, if any. Consistent with standard practice, most patients will likely be recommended against telling their relatives to seek genetic testing for the Variant of uncertain significance/VUS because it is not clinically useful. All participants with a VUS will be recommended to re-contact the MSK CGS in 1-2 years for updated information related to the VUS result

experimental: STRIVE Trial Intervention Arm: Digitally-Facilitated VUS Follow-Up

Following standard of care post-test genetic counseling, patients will be provided access to the MyGene Portal. Through this portal, participants will be able to continuously engage with interactive educational materials including information about Variant of uncertain significance/VUS results and recommendations, access tools for participants to communicate with the CGS team, access the interactive pedigree (FamGenix) to provide updates about personal/family medical history, receive notifications about VUS reclassification, and receive reminders to self-schedule a follow-up clinical visit to discuss updates. In this way, participants will have a transparent, ongoing, and structured follow-up plan for their VUS management.

no intervention: EfFORT Trial De-Identified Non-Randomized Control Arm

This control arm is comparable to true standard of care.

Interventions

Intervention Arm At-risk Relative/ARR Contacts

Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.

MyGene Portal

Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.

Standard of Care

Participants will received appropriate clinical care as outline by standard of care guidelines

Primary outcome measure

  • Comparison of genetic testing uptake in provider-facilitated cascade testing intervention to the proband-mediated cascade testing control [ Time Frame: 12 months ]
  • Comparison of participant perceived quality of care [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Kenneth Offit, MD, MPH

646-888-4059offitk@mskcc.org

Zsofia Stadler, MD

646-888-4039stadlerz@mskcc.org

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Kenneth Offit, MD, MPH

646-888-4059

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Kenneth Offit, MD, MPH

646-888-4059

Memorial Sloan Kettering Bergen (Limited Protocol Activity)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Kenneth Offit, MD, MPH

646-888-4059

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Kenneth Offit, MD, MPH

646-888-4059

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Kenneth Offit, MD, MPH

646-888-4059

Memorial Sloan Kettering Cancer Center

Recruiting

New York, New York, United States, 10021

Contacts

Kenneth Offit, MD, MPH

646-888-4059

MSK at Ralph Lauren (Limited Protocol Activities)

Recruiting

New York, New York, United States, 10035

Contacts

Kenneth Offit, MD, MPH

646-888-4059

Memorial Sloan Kettering Nassau (Limited Protocol Activity)

Recruiting

Uniondale, New York, United States, 11553

Contacts

Kenneth Offit, MD, MPH

646-888-4059

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Aug 27, 2026

Last verified

Aug, 2026

Keywords

  • EfFORT
  • Memorial Sloan Kettering Cancer Center
  • Genetic Testing
  • 22-023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-08-27.